Oyler称四大竞争优势构成复利循环，公司将持续投入以打造全球领先的肿瘤公司。
这些优势形成自我强化的反馈循环，使我们能够规模化地实现行业领先的研发回报，将创新转化为盈利增长，并为下一代药物提供不断增加的投入。每一轮循环都会强化下一轮。原文 (en)
These advantages create a self-reinforcing feedback loop. Together, they enable us to drive industry-leading R&D returns at scale, turn that innovation into profitable growth, and to fund a growing level of investment in next-generation medicines. Each turn of the cycle strengthens the next.
Oyler称BeOne是唯一在B细胞恶性肿瘤三大机制上均拥有潜在同类最佳药物的公司，竞争地位独特。
凭借BRUKINSA、BEQALZI和tacabrutideg，我们是唯一一家在B细胞恶性肿瘤三大关键作用机制上都拥有潜在同类最佳药物的公司。无论患者需要持续治疗、固定疗程还是进展后的选择，我们都能单药或联合满足需求。没有其他公司能做到这一点。原文 (en)
With BRUKINSA, BEQALZI, and tacabrutideg, we are the only company with potentially best-in-class medicines across the three key mechanisms of action in B-cell malignancies. So whether a patient wants continuous or fixed-duration therapy, or requires an option after progression, we will be able to meet the need with the right medicine, alone or in combination. No other company is positioned to do that.
Oyler认为BeOne实体瘤管线产出罕见，五个项目几乎同时推进至注册性开发。
大多数公司只有一个令人兴奋的资产，有些有两个。仅我们实体瘤管线的第一波就有五个，几乎同时推进至注册性开发。原文 (en)
Most companies have just one exciting asset. Some have two. From just the first wave of our solid tumor pipeline, we have five, all advancing towards registration-enabling development in roughly the same time.
Oyler称CDK4抑制剂和B7-H4 ADC两年半内从首次人体试验进入关键性开发，体现全球开发体系的速度。
两者从首次人体试验到关键性开发仅用了两年半，使我们得以迅速缩小与竞争对手的差距。如今管线推进至注册试验，使BeOne跻身极少数肿瘤创新者之列。原文 (en)
Both moved from first in human to pivotal development in just two and a half years, allowing us to rapidly close the gap with the competition. Now we are seeing that pipeline advance into registrational trials, which puts BeOne in an exceptionally select group of oncology innovators.